Senhwa Biosciences, Inc.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.senhwabio.com

Country

Taiwan

Exchange

Taipei Exchange

Senhwa Biosciences develops novel drugs and special active pharmaceutical ingredients. The company offers novel drugs, a small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) for the treatment of breast cancer and homologous repair deficiency (HRD) or solid tumors from BRCA1/2 gene mutation.

Its portfolio also includes inhibitor of protein kinase CK2 (casein kinase II), and Silmitasertib (CX4945) for the treatment of cholangiocarcinoma, basal cell carcinoma, and medulloblastoma Technical advice and consulting services. Senhwa Biosciences, Inc. is based in New Taipei City, Taiwan.

Key Stats

52-Week Range

NT$34.35NT$66.50

Beta0.89

Trailing P/EN/A

Forward P/E-83.80

Trailing EPS-2.92

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.